Long-Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 Genotype. - Wikidata - awgldk - TriplyDB

Long-Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 Genotype.

Long-Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 Genotype.

http://www.wikidata.org/entity/Q40750400

about

Tacrolimus Trough Concentration Variability and Disparities in African American Kidney Transplantation.Pharmacogenetic aspects of the use of tacrolimus in renal transplantation: recent developments and ethnic considerations.New formulations of tacrolimus and prevention of acute and chronic rejections in adult kidney-transplant recipients.Transplant genetics and genomics.Impact of CYP3A5 genomic variances on clinical outcomes among African American kidney transplant recipients.Concepts of Genomics in Kidney Transplantation.CYP3A genotypes of donors but not those of the patients increase the risk of acute rejection in renal transplant recipients on calcineurin inhibitors: a pilot study.Failure of Calcineurin Inhibitor (Tacrolimus) Weaning Randomized Trial in Long-Term Stable Kidney Transplant Recipients.Clinical impact of the CYP3A5 6986A>G allelic variant on kidney transplantation outcomes.Which Kidney Transplant Recipients Can Benefit from the Initial Tacrolimus Dose Reduction?Pharmacokinetic considerations related to therapeutic drug monitoring of tacrolimus in kidney transplant patients.

P2860

Q38704635-750B7103-789D-4929-A92D-1B1A98F769D0 Q38787174-417B265E-004E-40B9-90C1-63ECD507C331 Q38791651-38EB77CD-E0FD-4A77-84D8-732DE5430516 Q39175303-B19D5ED9-E86F-4853-85D2-E77BF29A737B Q46357849-9D2DD616-3EE9-4923-86F4-665018D9165F Q46684824-D89E55B3-BB3A-4F5D-9E9C-534C1625BD4C Q48172244-F7E28A2C-B228-4E67-BC74-30E55E9676AA Q48955797-E96DB500-273B-4A92-B70E-255490A8EA76 Q51262438-BB7E08C0-0DDC-4D83-9C9C-0D505C33AB89 Q52590662-36CF7AD5-D424-4954-8E83-768346DC6799 Q52859440-3246FD34-C229-4D90-A5B8-AB8A2C213B92

P2860

Long-Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 Genotype.

http://www.wikidata.org/entity/Q40750400

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Long-Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 Genotype.

@en

type

label

Long-Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 Genotype.

@en

prefLabel

Long-Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 Genotype.

@en

P1433

Q40750400-872483F7-EB5B-434A-9E7B-3F7FF94C5B4A

P1476

Q40750400-3BCEC1E9-6C1F-4E52-AB3C-FA1A99ECE3AD

P2093

Q40750400-26458D89-29C1-4938-A41A-4F9D80B235E0

Q40750400-37EF5B17-B786-41E3-94F6-B740C58F38F6

Q40750400-3E57C366-13F3-4EAC-9DD8-E538320EC02D

Q40750400-46ED07C9-BB11-4648-A122-B5E100F77D6C

Q40750400-5EB3D479-A775-4626-99A7-4F3051000A59

Q40750400-623333DD-E511-49C6-8606-4671E16DC6E7

Q40750400-741907CC-0FF9-48FF-8A40-121C83289032

Q40750400-9952056C-BFD2-4CE2-A26C-DFDFEC6A64D4

Q40750400-AC3F8568-DB5F-49DD-A25A-D59D3A3D57B5

Q40750400-BD317B15-DE6A-46F0-9EFE-9D8820BB0C09

P2860

Q40750400-0EE3455D-C411-4AF5-9E3E-81DBF4AAE061

Q40750400-2ABC0C55-7E1D-49B4-BB3B-8C0A00B3E93C

Q40750400-4760EB2E-FA2C-4E70-8294-9099FF9A0F0F

Q40750400-4CD07705-AC5E-4C62-A746-D43E0483E138

Q40750400-53283953-2D16-4605-A620-DD09955E2F56

Q40750400-6D852290-5CF1-42C4-8219-57DECFCAC60A

Q40750400-8DEEC525-DBF0-44CE-8085-C2325389728C

Q40750400-A2594C73-65E8-4E17-ABD6-A5F1784AA6EF

Q40750400-B8E262C9-668C-4F90-A219-3F3FB0B3D722

Q40750400-BB7E3AEA-458A-4C69-9630-8161E65EDAA8

P304

Q40750400-AB4AEC7A-DD54-4AEE-9A3F-C85C3FAD3BD0

P31

Q40750400-4D8538B6-4563-4496-A2C7-CA1954BB56D1

P356

Q40750400-DD71CFCC-B064-44C1-83AF-40D59D91B892

P407

Q40750400-CDFC2400-A103-4F01-90A4-74B44C6D6887

P433

Q40750400-0341820D-93B4-4F48-8E01-9F6DF92E833A

P478

Q40750400-F960A4E4-04E0-4797-B33B-F232C40CAB08

P50

Q40750400-36C1493A-1B85-4BC0-9ACC-28233620A634

Q40750400-375B5AA7-73C2-47AC-9557-00C9B381C605

Q40750400-383AD4DB-94EB-471D-86E6-67A375F61E34

Q40750400-4CF0223E-0F88-43AF-90AC-D436DDADB495

Q40750400-FCC24A16-7AB9-40AC-AD7E-56E34A1C2F2D

P577

Q40750400-7ACE09C7-60C5-40C3-AB92-DFA02E8B1EB5

P698

Q40750400-D4899BBD-EE00-4E51-8ABE-9F9EC37219AF

P356

P1433

American Journal of Transplantation

P1476

Long-Term Clinical Impact of Adaptation of Initial Tacrolimus Dosing to CYP3A5 Genotype.

@en

P2093

A Thierry

http://www.w3.org/2001/XMLSchema#string

A-E Heng

http://www.w3.org/2001/XMLSchema#string

B Hurault de Ligny

http://www.w3.org/2001/XMLSchema#string

C Colosio

http://www.w3.org/2001/XMLSchema#string

C Legendre

http://www.w3.org/2001/XMLSchema#string

C Vigneau

http://www.w3.org/2001/XMLSchema#string

E Bailly

http://www.w3.org/2001/XMLSchema#string

E Thervet

http://www.w3.org/2001/XMLSchema#string

G Choukroun

http://www.w3.org/2001/XMLSchema#string

I Etienne

http://www.w3.org/2001/XMLSchema#string

P2860

KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer.

Improved Tacrolimus Target Concentration Achievement Using Computerized Dosing in Renal Transplant Recipients--A Prospective, Randomized Study.

Donor ABCB1 variant associates with increased risk for kidney allograft failure.

Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference.

Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks.

The effect of CYP3A5 6986A>G and ABCB1 3435C>T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients: a systematic review and meta-analysis.

Pharmacogenetics in kidney transplantation: recent updates and potential clinical applications.

Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies.

Prospective DPYD genotyping to reduce the risk of fluoropyrimidine-induced severe toxicity: Ready for prime time.

The challenge of achieving target drug concentrations in clinical trials: experience from the Symphony study.

P304

2670-2675

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/AJT.13788

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

16

http://www.w3.org/2001/XMLSchema#string

P50

Yannick Le Meur

Marie-Anne Loriot

Philippe Beaune

P577

2016-03-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26990694

http://www.w3.org/2001/XMLSchema#string